News | Contrast Media | May 15, 2023

Elucirem, a novel new macrocyclic GBCA for use in contrast-enhanced magnetic resonance imaging (MRI), has the highest relaxivity compared to other non-specific GBCAs (gadolinium-based contrast agents)

Elucirem, a novel new macrocyclic GBCA for use in contrast-enhanced magnetic resonance imaging (MRI), has the highest relaxivity compared to other non-specific GBCAs (gadolinium-based contrast agents)

May 15, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced that based on the most recent scientific and clinical evidence, the ACR Committee on Drugs and Contrast Media has classified Elucirem (gadopiclenol) as a Group II agent.6 This next generation GBCA from Guerbet, highly stable macrocyclic gadolinium-based contrast agent (GBCA), has the highest relaxivity in its class for magnetic resonance imaging (MRI) and is indicated for use in adults and children aged 2 years and older.1,4 Elucirem requires only half the gadolinium dose of conventional non-specific GBCAs, addressing practitioners' concerns about gadolinium exposure.2,3

"This new classification from the ACR is a real game changer for the future of Elucirem," said Jared Houk, Commercial Vice President at Guerbet. "This is an important moment for our team as it really shows the benefit of this product and its potential in the market."

The classification states that gadopiclenol "demonstrates kinetic stability and a long dissociation half-life that are comparable to other Group II macrocyclic agents. Based on the most recent scientific and clinical evidence, the ACR Committee on Drugs and Contrast Media considers the risk of NSF among patients exposed to standard or lower than standard doses of Gadopiclenol is sufficiently low or possibly nonexistent such that it has been classified as a Group II agent."6

Elucirem (Gadopiclenol) injection is used to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).1 Guerbet received FDA approval of Elucirem (NDA 216986) on September 21, 2022 after priority review, a designation assigned to applications for drugs that provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions compared to available therapies.5 

GBCAs improve the contrast between lesions and surrounding tissues by accelerating the relaxation of protons thanks to interaction with gadolinium atoms. Gadopiclenol, the active drug substance of Elucirem, has been designed to enable twice as much interaction, resulting in the highest relaxivity among all non-specific GBCAs.4 This allows use at half the conventional gadolinium dose to reveal high quality images.

Elucirem is manufactured by Liebel-Flarsheim Company LLC, a Guerbet Group company, in Raleigh, North Carolina.

For more information: www.guerbet.com

References: 

 

1Elucirem [package insert]. Princeton, NJ: Guerbet LLC; 2022
2Loevner LA, Kolumban B, Hutóczki G, et al. Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial. Investigative Radiology ():10.1097/RLI.0000000000000944, December 19, 2022. | DOI: 10.1097/RLI.0000000000000944
3Data on file (PROMISE trial. GDX-44-011)
4 Robic, C., Port, M., Rousseaux, O., Louguet, S., Fretellier, N., Catoen, S., Factor, C., Le Greneur, S., Medina, C., Bourrinet, P., Raynal, I., Idée, J. M., & Corot, C. (2019). Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity. Investigative radiology, 54(8), 475–484. https://doi.org/10.1097/RLI.0000000000000563  
5 US FDA. Priority Review. Available at: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review.  Accessed August 22, 2022 
ACR Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. April 2023.

Related Content: 

Efficacy and Safety of Gadopiclenol with Contrast-enhanced MRI of the Central Nervous System Published

Guerbet Announces FDA Approval of Elucirem (Gadopiclenol) for Use in Contrast-enhanced MRI 

Contrast Media Supply Shortage: How and What Now? 

FDA Grants Import Discretion of Bracco’s Iodinated Contrast Medium Iomeron (iomeprol injection) to Address Supply Shortages 

Guerbet to Spotlight the Novel New Drug Elucirem (gadopiclenol) injection at RSNA22 


Related Content

Feature | Magnetic Resonance Imaging (MRI) | By Robert L. Bard, MD, and Lennard M. Gettz, EdD

Since the advent of the magnetic resonance imaging (MRI) exam on human patients in the late 1970s, this innovation ...

Time September 25, 2023
arrow
News | Prostate Cancer

September 22, 2023 — According to an accepted manuscript published in the American Journal of Roentgenology (AJR) ...

Time September 22, 2023
arrow
News | Contrast Media

September 21, 2023 — Imaging Biometrics, LLC announced the results of a study that validates IB Neuro’s processing of ...

Time September 21, 2023
arrow
Feature | Proton Therapy | By Christine Book

An overview of significant developments in proton therapy, over just the past six months, reinforces the pace of ...

Time September 21, 2023
arrow
Sponsored Content | Case Study | Radiology Imaging | By Tim Hodson

In June, the Philips Radiology Experience Tour hit the road to provide healthcare professionals with an opportunity to ...

Time September 19, 2023
arrow
Feature | Magnetic Resonance Imaging (MRI) | By Christine Book

The world of medical imaging is marking a significant milestone in 2023: the 50th anniversary of magnetic resonance ...

Time September 19, 2023
arrow
News | SNMMI

September 18, 2023 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI), as a professional society ...

Time September 18, 2023
arrow
News | Ultrasound Imaging

September 15, 2023 — Contrast enhanced ultrasound (CEUS) is underutilized in the United States, and reduced access to ...

Time September 15, 2023
arrow
News | Lung Imaging

September 11, 2023 — Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced magnetic ...

Time September 11, 2023
arrow
Feature | PET Imaging

According to a new report from Transparency Market Research (TMR), PET radiotracers are expected to rise at a CAGR of 8 ...

Time September 05, 2023
arrow
Subscribe Now